US20210071118A1 - Compositions, their manufacture and use - Google Patents

Compositions, their manufacture and use Download PDF

Info

Publication number
US20210071118A1
US20210071118A1 US16/763,430 US201816763430A US2021071118A1 US 20210071118 A1 US20210071118 A1 US 20210071118A1 US 201816763430 A US201816763430 A US 201816763430A US 2021071118 A1 US2021071118 A1 US 2021071118A1
Authority
US
United States
Prior art keywords
salt
enzyme
alkyl
acid
subtilisin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/763,430
Other languages
English (en)
Inventor
Stephan Hueffer
Alejandra GARCIA MARCOS
Susanne Wolwertz
Monika Neufeld
Matthias Kellermeier
Grit Baier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Assigned to BASF SE reassignment BASF SE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KELLERMEIER, Matthias, GARCIA MARCOS, ALEJANDRA, WOLWERTZ, Susanne, HUEFFER, STEPHAN
Assigned to BASF SE reassignment BASF SE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KELLERMEIER, Matthias, BAIER, Grit, HUEFFER, STEPHAN, WOLWERTZ, Susanne, GARCIA MARCOS, ALEJANDRA, NEUFELD, Monika
Publication of US20210071118A1 publication Critical patent/US20210071118A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/26—Organic compounds containing nitrogen
    • C11D3/30—Amines; Substituted amines ; Quaternized amines
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38663—Stabilised liquid enzyme compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C11D11/0017—
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3707—Polyethers, e.g. polyalkyleneoxides
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38618—Protease or amylase in liquid compositions only
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38627—Preparations containing enzymes, e.g. protease or amylase containing lipase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38636—Preparations containing enzymes, e.g. protease or amylase containing enzymes other than protease, amylase, lipase, cellulase, oxidase or reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D2111/00—Cleaning compositions characterised by the objects to be cleaned; Cleaning compositions characterised by non-standard cleaning or washing processes
    • C11D2111/10—Objects to be cleaned
    • C11D2111/12—Soft surfaces, e.g. textile

Definitions

  • the present invention is directed towards a composition containing
  • compositions and especially detergent compositions are made for various cleaning applications, for example laundry or automatic dishwashing. All of them have to fulfil many different requirements. While solid compositions play a traditional role, in the meantime liquid compositions also have their merits. They can be completely transferred into a laundromat without leaving residues of unused detergent in the dosage unit. Especially for so-called color laundry detergents, liquid laundry detergents are of great importance.
  • Detergent manufacturer demand a great flexibility from the ingredients they use, including the builders.
  • a well-known builder is sodium citrate, the trisodium salt of citric acid.
  • Sodium citrate is suitable for use as a builder in heavy duty laundry detergents because of its ability to sequester calcium and magnesium ions found in tap water and, unlike phosphate builders, it is environmentally safe. It is especially suitable for use in liquid detergent formulations because, unlike other environmentally safe detergent builders, trisodium citrate is well soluble.
  • a minimum water content of 30% by weight is usually required, though. This requirement limits the flexibility of the laundry detergent manufacturers. This requirement turns out to be even more detrimental in view of the modern trend within this industry, namely downsizing of dosage units (pouches) and therefore reducing the water content.
  • compositions that allows a flexible formulation, even with high or low water content. It was further the objective to provide a composition that has excellent shelf life, especially with respect to the enzyme(s) contained therein. It was further an objective to provide a method for making such compositions, and it was further an objective to provide uses of such compositions.
  • compositions as defined at the outset have been found, hereinafter also defined as inventive compositions or as compositions according to the present invention.
  • inventive compositions contain
  • Salt (A) is a salt of an organic ester of choline or of a derivative of choline.
  • inorganic counterions of salt (A) are nitrate, hydroxide, sulphate, phosphate, hydrogenphosphate, dihydrogenphosphate, carbonate, bicarbonate, and halide, for example bromide or chloride.
  • Preferred are halide, especially chloride, and sulphate, carbonate, and bicarbonate.
  • organic counterions are lactate, acetate, tartrate, citrate, and CH 3 SO 3 ⁇ (methanesulfonate).
  • the respective molar amounts cation is present.
  • the nitrogen atom in salt (A) bears three methyl groups and a hydroxyethyl group.
  • derivatives of choline refers to compounds that bear at least one alkyl group other than a methyl group, or a hydroxyalkyl group other than a 2-hydroxyethyl group, or further alkoxy groups.
  • salt (A) is a compound of general formula (1)
  • n is selected from 1 to 12, for example 1 to 9, preferably 1, 2, 3, or 4, and even more preferably n is 1,
  • n is selected from zero to 50, for example 2 to 50, preferred is 10 to 25. Most preferably, however, m is zero.
  • R 1 is selected from C 1 -C 10 -alkyl, linear or branched, and C 6 -C 10 -aryl, wherein R 1 may bear one or more hydroxyl or C ⁇ O or COOH groups, partially or fully neutralized, if applicable.
  • R 1 are non-substituted C 1 -C 6 -alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, n-hexyl, preferred non-substituted C 1 -C 10 -alkyl are methyl and ethyl, furthermore substituted such C 1 -C 10 -alkyl as —CH(OH)—CH(OH)—COOH, CH(OH)—CH 3 , (E)-CH ⁇ CHCOOH, (Z)—CH ⁇ CHCOOH, —C 6 H 5 , para-HO—C 6 H 4 —, o,p-dihydroxyphenyl, and 3,4,5-triydroxyphenyl.
  • O—C(O)—R 1 together constitute a citrate. Even more preferred, R 1 is methyl.
  • R 2 are same or different and selected from phenyl and C 1 -C 10 -alkyl, for example methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl, tert.-butyl, n-pentyl, iso-pentyl, sec.-pentyl, neo-pentyl, 1,2-dimethylpropyl, iso-amyl, n-hexyl, iso-hexyl, sec.-hexyl, n-heptyl, n-octyl, 2-ethylhexyl, n-nonyl, n-decyl, 2-n-propyl-heptyl, or iso-decyl, preferred are linear C 1 -C 10 -alkyl and more preferred are linear C 1 -C 4 -alkyl, Even more preferred at
  • R 3 and R 4 are same or different and selected from hydrogen and C 1 -C 4 -alkyl, preferred are n- for example methyl, ethyl, n-propyl, and n-butyl, and even more preferred both R 3 and R 4 are hydrogen.
  • R 3 is C 1 -C 4 -alkyl and R 4 is hydrogen, preferably R 3 is methyl and R 4 is hydrogen.
  • X is C 2 -C 4 -alkylen, for example —CH 2 —CH 2 —, —CH(CH 3 )—CH 2 —, —(CH 2 ) 3 —, CH 2 —CH(CH 3 )—, or —(CH 2 ) 4 —, and
  • a ⁇ is a counteranion, inorganic or organic.
  • inorganic counterions of salt (A) are sulphate, phosphate, hydrogenphosphate, dihydrogenphosphate, carbonate, bicarbonate, and halide, for example bromide or chloride. Preferred are halide, especially chloride, and sulphate, carbonate, and bicarbonate.
  • organic counterions are lactate, acetate, tartrate, citrate, and CH 3 SO 3 ⁇ (methanesulfonate).
  • salts (A) are salts of choline esters with tartrate or citrate as counterion, and salts of acetyl choline, choline citrate, and of choline tartrate, for example lactates, acetates, tartrates, citrates.
  • Component (a) is not a surfactant.
  • a solution of 5 g component (a) in 1000 g water has a dynamic surface tension of >45 mN/m at 20° C. and 101.3 kPa.
  • a solution of 5 g component (a) in 1000 g water may have a dynamic surface tension of >50 mN/m at 20° C. and 101.3 kPa.
  • the dynamic surface tension may be measured with a bubble pressure tensiometer, wherein the maximum internal pressure of a gas bubble which is formed in a liquid by means of a capillary is measured; the measured value usually corresponds to the surface tension at a certain surface age, the time from the start of the bubble formation to the occurrence of the pressure maximum.
  • the surface age during measuring the dynamic surface tension at 20° C. and 101.3 kPa with a bubble pressure tensiometer is 50 ms.
  • counteranion A ⁇ is—or may be—divalent such as sulphate, tartrate, carbonate, or polyvalent such as phosphate or citrate
  • the necessary positive charge may be furnished by another salt (A) derived cation, or by alkali metal cations such as potassium or preferably sodium, or by ammonium, non-substituted or substituted with C 1 -C 4 -alkyl and/or with 2-hydroxyethyl.
  • R 1 bears one or more carboxyl groups they may be free COOH groups or partially or fully neutralized with alkali, for example potassium or especially sodium, or they may be esterified, for example with (R 2 ) 3 N + —(CH 2 ) n —(O—X) m OH.
  • alkali for example potassium or especially sodium
  • R 2 may be esterified, for example with (R 2 ) 3 N + —(CH 2 ) n —(O—X) m OH.
  • Such embodiments result in the di- or triester, if applicable, of the respective di- or tricarboxylic acid.
  • Mixtures of mono- and diesters of, e.g., tartaric acid or citric acid, and mixtures of di- and triesters of citric acid are feasible as well.
  • salt (A) is selected from
  • (A 1 ) ⁇ is selected from methanesulfonate, tartrate and citrate and wherein R 5 is selected from —CH 2 —C(OH)(COOX 2 )—CH 2 —COOX 2 and —CH(OH)—CH(OH)—COOX 1
  • X 1 is selected from hydrogen, alkali metal—especially sodium—and (CH 3 ) 3 N + —(CH 2 ) 2 — and wherein X 2 are same or different and selected from hydrogen, alkali metal—especially sodium—and (CH 3 ) 3 N + —(CH 2 ) 2 —.
  • the ester group of O—C(O)—R 5 and (A 1 ) ⁇ correspond to each other.
  • inventive compositions contain in the range of from 0.5 to 30% by weight of salt (A), referring to the entire composition, preferably 0.5 to 6% by weight and more preferably 1 to 3% by weight.
  • salt (A) contains as an impurity a compound (A′)
  • impurity may amount to up to 50 mole-%, preferably 0.1 to 20 mole-%, even more preferably 1 to 10 mole-% of salt (A).
  • impurity (A′) may stem from the synthesis of salt (A) and may be removed by purification methods it is not preferred to remove it.
  • compositions further contain at least one surfactant (B) selected from amphoteric surfactants and especially from anionic surfactants and non-ionic surfactants, hereinafter also referred to as amphoteric surfactants (B), anionic surfactants (B) and non-ionic surfactants (B), respectively.
  • B surfactant selected from amphoteric surfactants and especially from anionic surfactants and non-ionic surfactants, hereinafter also referred to as amphoteric surfactants (B), anionic surfactants (B) and non-ionic surfactants (B), respectively.
  • Suitable anionic surfactants (B) are alkali metal and ammonium salts of C 8 -C 18 -alkyl sulfates, of C 8 -C 18 -fatty alcohol polyether sulfates, of sulfuric acid half-esters of ethoxylated C 4 -C 12 -alkylphenols (ethoxylation: 1 to 50 mol of ethylene oxide/mol), C 12 -C 18 sulfo fatty acid alkyl esters, for example of C 12 -C 18 sulfo fatty acid methyl esters, furthermore of C 12 -C 18 -alkylsulfonic acids and of C 10 -C 18 -alkylarylsulfonic acids.
  • anionic surfactants (B) are compounds according to general formula (III)
  • surfactant (B) the variables s and t may be average numbers and therefore they are not necessarily whole numbers, while in individual molecules according to formula (III), both s and t denote whole numbers.
  • Suitable anionic surfactants (B) are soaps, for example the sodium or potassium salts of stearic acid, oleic acid, palmitic acid, ether carboxylates, and alkylether phosphates.
  • Preferred non-ionic surfactants (B) are alkoxylated alcohols, di- and multiblock copolymers of ethylene oxide and propylene oxide and reaction products of sorbitan with ethylene oxide or propylene oxide, alkyl polyglycosides (APG), hydroxyalkyl mixed ethers and amine oxides.
  • alkoxylated alcohols and alkoxylated fatty alcohols are, for example, compounds of the general formula (IV)
  • m and x are in the range from zero to 300, where the sum of n and m is at least one, preferably in the range of from 3 to 50.
  • m is in the range from 1 to 100 and x is in the range from 0 to 30.
  • compounds of the general formula (III) may be block copolymers or random copolymers, preference being given to block copolymers.
  • alkoxylated alcohols are, for example, compounds of the general formula (V)
  • the sum a+b+d is preferably in the range of from 5 to 100, even more preferably in the range of from 9 to 50.
  • Preferred examples for hydroxyalkyl mixed ethers are compounds of the general formula (VI)
  • m and x are in the range from zero to 300, where the sum of n and m is at least one, preferably in the range of from 5 to 50.
  • m is in the range from 1 to 100 and n is in the range from 0 to 30.
  • Compounds of the general formulae (V) and (VI) may be block copolymers or random copolymers, preference being given to block copolymers.
  • non-ionic surfactants are selected from di- and multiblock copolymers, composed of ethylene oxide and propylene oxide. Further suitable non-ionic surfactants are selected from ethoxylated or propoxylated sorbitan esters. Amine oxides or alkyl polyglycosides, especially linear C 4 -C 18 -alkyl polyglucosides and branched C 8 -C 18 -alkyl polyglycosides such as compounds of general average formula (VII) are likewise suitable.
  • non-ionic surfactants are compounds of general formula (VIII) and (IX)
  • Mixtures of two or more different non-ionic surfactants (B) may also be present.
  • surfactants that may be present are selected from amphoteric (zwitterionic) surfactants and anionic surfactants and mixtures thereof.
  • amphoteric surfactants (B) are those that bear a positive and a negative charge in the same molecule under use conditions.
  • Preferred examples of amphoteric surfactants are so-called betaine-surfactants.
  • Many examples of betaine-surfactants bear one quaternized nitrogen atom and one carboxylic acid group per molecule.
  • a particularly preferred example of amphoteric surfactants is cocamidopropyl betaine (lauramidopropyl betaine).
  • amine oxide surfactants are compounds of the general formula (X)
  • R 13 , R 14 and R 15 are selected independently from each other from aliphatic, cycloaliphatic or C 2 -C 4 -alkylene C 10 -C 20 -alkylamido moieties.
  • R 12 is selected from C 8 -C 20 -alkyl or C 2 -C 4 -alkylene C 10 -C 20 -alkylamido and R 13 and R 14 are both methyl.
  • a particularly preferred example is lauryl dimethyl aminoxide, sometimes also called lauramine oxide.
  • a further particularly preferred example is cocamidylpropyl dimethylaminoxide, sometimes also called cocamidopropylamine oxide.
  • inventive compositions contain 0.1 to 60% by weight of surfactant (B), preferably selected from anionic surfactants (B), non-ionic surfactants (B), amphoteric surfactants (B) and amine oxide surfactants as well as combinations of at least two of the foregoing.
  • inventive compositions contain 5 to 30% by weight of anionic surfactant and at least one non-ionic surfactant, for example in the range of from 3 to 20% by weight.
  • compositions may be liquid at ambient temperature (20° C.). Preferably, they are stable liquids at ambient temperature.
  • stable means that such inventive compositions are liquid and do not show traces of precipitate formation or turbidity even after 20 days of storage.
  • inventive compositions are aqueous, typically containing in the range of from 5 to 95% by weight water, for example 5 to 30% by weight and more preferred 5 to 25% by weight, or 20 to 70% by weight water and zero to 20% by weight organic solvent. Preferred is 5 to 15% by weight of water and no significant amounts of organic solvent, for example 1% by weight or less.
  • compositions may be alkaline or exhibit a neutral or slightly acidic pH value, for example 6 to 14, preferably 6.5 to 13, more preferably 8 to 10.5 and most preferably 8.5 to 9.0.
  • inventive compositions additionally comprise
  • enzymes (C) in inventive compositions exhibit a particularly high life-time.
  • Enzymes (C) that are particularly beneficial in inventive compositions are selected from hydrolases (EC 3).
  • Preferred enzymes (C) are selected from the group of enzymes acting on ester bond (E.C. 3.1), glycosylases (E.C. 3.2), and peptidases (E.C. 3.4).
  • Enzymes acting on ester bond (E.C. 3.1), hereinafter also refer to lipases (component (b)), respectively.
  • Glycosylases (E.C. 3.2) hereinafter also refer to either amylases (C) and cellulases (C).
  • Peptidases hereinafter also refer to proteases (C).
  • Hydrolases (C) in the context of the present invention are identified by polypeptide sequences, also called amino acid sequences herein.
  • the polypeptide sequence specifies the three-dimensional structure including the “active site” of an enzyme which in turn determines the catalytic activity of the same.
  • Polypeptide sequences may be identified by a SEQ ID NO. According to the World Intellectual Property Office (WIPO) Standard ST.25 (1998) the amino acids herein are represented using three-letter code with the first letter as a capital or the corresponding one letter.
  • Enzymes (C) in the context of the present invention may relate to parent enzymes and/or variant enzymes, both having enzymatic activity. Enzymes having enzymatic activity are enzymatically active or exert enzymatic conversion, meaning that enzymes act on substrates and convert these into products.
  • a “parent” sequence of a parent protein or enzyme, also called “parent enzyme” is the starting sequence for introduction of changes, e.g., by introducing one or more amino acid substitutions, insertions, deletions, or a combination thereof to the sequence, resulting in “variants” of the parent sequences.
  • the term parent enzyme (or parent sequence) includes wild-type enzymes (sequences) and synthetically generated sequences (enzymes) which are used as starting sequences for introduction of (further) changes.
  • enzyme variant or “sequence variant” or “variant enzyme” refers to an enzyme that differs from its parent enzyme in its amino acid sequence to a certain extent. If not indicated otherwise, variant enzyme “having enzymatic activity” means that this variant enzyme has the same type of enzymatic activity as the respective parent enzyme.
  • Amino acid substitutions are described by providing the original amino acid of the parent enzyme followed by the number of the position within the amino acid sequence, followed by the substituted amino acid.
  • Amino acid deletions are described by providing the original amino acid of the parent enzyme followed by the number of the position within the amino acid sequence, followed by *.
  • Amino acid insertions are described by providing the original amino acid of the parent enzyme followed by the number of the position within the amino acid sequence, followed by the original amino acid and the additional amino acid. For example, an insertion at position 180 of lysine next to glycine is designated as “Gly180GlyLys” or “G180GK”.
  • Arg170Tyr, Glu represents a substitution of arginine at position 170 with tyrosine or glutamic acid.
  • Arg170Tyr, Glu represents a substitution of arginine at position 170 with tyrosine or glutamic acid.
  • different alterations or optional substitutions may be indicated in brackets e.g. Arg170[Tyr, Gly] or Arg170 ⁇ Tyr, Gly ⁇ ; or in short R170 [Y,G] or R170 ⁇ Y, G ⁇ ; or in long R170Y, R170G.
  • Enzyme variants may be defined by their sequence identity when compared to a parent enzyme. Sequence identity usually is provided as “% sequence identity” or “% identity”. For calculation of sequence identities, in a first step a sequence alignment has to be produced. According to this invention, a pairwise global alignment has to be produced, meaning that two sequences have to be aligned over their complete length, which is usually produced by using a mathematical approach, called alignment algorithm.
  • the alignment is generated by using the algorithm of Needleman and Wunsch (J. Mol. Biol. 1979 48, p. 443-453).
  • the program “NEEDLE” The European Molecular Biology Open Software Suite (EMBOSS)
  • EMBOSS European Molecular Biology Open Software Suite
  • enzyme variants may be described as an amino acid sequence which is at least n % identical to the amino acid sequence of the respective parent enzyme with “n” being an integer between 10 and 100.
  • variant enzymes are at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical when compared to the full length amino acid sequence of the parent enzyme, wherein the enzyme variant has enzymatic activity.
  • Enzyme variants may be defined by their sequence similarity when compared to a parent enzyme. Sequence similarity usually is provided as “% sequence similarity” or “%-similarity”. % sequence similarity takes into account that defined sets of amino acids share similar properties, e.g by their size, by their hydrophobicity, by their charge, or by other characteristics. Herein, the exchange of one amino acid with a similar amino acid may be called “conservative mutation”.
  • Conservative amino acid substitutions may occur over the full length of the sequence of a polypeptide sequence of a functional protein such as an enzyme. In one embodiment, such mutations are not pertaining the functional domains of an enzyme. In one embodiment, conservative mutations are not pertaining the catalytic centers of an enzyme.
  • %-similarity [(identical residues+similar residues)/length of the alignment region which is showing the respective sequence(s) of this invention over its complete length]-100.
  • enzyme variants may be described as an amino acid sequence which is at least m % similar to the respective parent sequences with “m” being an integer between 10 and 100.
  • variant enzymes are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar when compared to the full length polypeptide sequence of the parent enzyme, wherein the variant enzyme has enzymatic activity.
  • Enzymatic activity means the catalytic effect exerted by an enzyme, which usually is expressed as units per milligram of enzyme (specific activity) which relates to molecules of substrate transformed per minute per molecule of enzyme (molecular activity).
  • Variant enzymes may have enzymatic activity according to the present invention when said enzyme variants exhibit at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at 10 least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the enzymatic activity of the respective parent enzyme.
  • inventive compositions comprise at least one protease (C).
  • Enzymes (C) having proteolytic activity are called “proteases” or peptidases in the context of the present invention.
  • Such enzymes are members of class EC 3.4.
  • Proteases (C) are further classified as aminopeptidases (EC 3.4.11), dipeptidases (EC 3.4.13), dipeptidyl-peptidases and tripeptidyl-peptidases (EC 3.4.14), peptidyl-dipeptidases (EC 3.4.15), serine-type carboxypeptidases (EC 3.4.16), metallocarboxypeptidases (EC 3.4.17), cysteinetype carboxypeptidases (EC 3.4.18), omega peptidases (EC 3.4.19), serine endopeptidases (EC 3.4.21), cysteine endopeptidases (EC 3.4.22), aspartic endopeptidases (EC 3.4.23), metallo-endopeptidases (EC 3.4.24), threonine endopeptidases (EC 3.4.25), or endopeptidases of unknown catalytic mechanism (EC 3.4.99).
  • Protease (C) may be an endopeptidase of any kind or a mixture of endopeptidases of any kind.
  • protease according to the invention is selected from serine protease (EC 3.4.21).
  • Serine proteases or serine peptidases are characterized by having a serine in the catalytically active site, which forms a covalent adduct with the substrate during the catalytic reaction.
  • a serine protease in the context of the present invention is selected from the group consisting of chymotrypsin (e.g., EC 3.4.21.1), elastase (e.g., EC 3.4.21.36), elastase (e.g., EC 3.4.21.37 or EC 3.4.21.71), granzyme (e.g., EC 3.4.21.78 or EC 3.4.21.79), kallikrein (e.g., EC 3.4.21.34, EC 3.4.21.35, EC 3.4.21.118, or EC 3.4.21.119,) plasmin (e.g., EC 3.4.21.7), trypsin (e.g., EC 3.4.21.4), thrombin (e.g., EC 3.4.21.5
  • Crystallographic structures of proteases (C) show that the active site is commonly located in a groove on the surface of the molecule between adjacent structural domains, and the substrate specificity is governed by the properties of binding sites arranged along the groove on one or both sides of the catalytic site that is responsible for hydrolysis of the scissile bond. Accordingly, the specificity of protease (C) can be described by use of a conceptual model in which each specificity subsite is able to accommodate the sidechain of a single amino acid residue.
  • the sites are numbered from the catalytic site, S1, S2 . . . Sn towards the N-terminus of the substrate, and S1′, S2′ . . . Sn′ towards the C-terminus.
  • the residues they accommodate are numbered P1, P2 . . . Pn, and P1′, P2′ . . . Pn′, respectively:
  • protease activity In general, the three main types of protease activity (proteolytic activity) are: trypsin-like, where there is cleavage of amide substrates following Arg (N) or Lys (K) at P1, chymotrypsin-like where cleavage occurs following one of the hydrophobic amino acids at P1, and elastase-like with cleavage following an Ala (A) at P1.
  • subtilases A sub-group of the serine proteases tentatively designated as subtilases has been proposed by Siezen et al. (1991), Protein Eng. 4:719-737 and Siezen et al. (1997), Protein Science 6:501-523. They are defined by homology analysis of more than 170 amino acid sequences of serine proteases previously referred to as subtilisin-like proteases. A subtilisin was previously often defined as a serine protease produced by Gram-positive bacteria or fungi, and according to Siezen et al. now is a subgroup of the subtilases. A wide variety of subtilases have been identified, and the amino acid sequence of a number of subtilases has been determined.
  • subtilases may be divided into 6 sub-divisions, i.e. the subtilisin family, the thermitase family, the proteinase K family, the lantibiotic peptidase family, the kexin family and the pyrolysin family.
  • subtilases A subgroup of the subtilases are the subtilisins which are serine proteases from the family S8 as defined by the MEROPS database (http://merops.sanger.ac.uk).
  • Peptidase family S8 contains the serine endopeptidase subtilisin and its homologues.
  • subfamily S8A the active site residues frequently occur in the motifs Asp-Thr/Ser-Gly similarly to the sequence motif in families of aspartic endopeptidases in clan AA, His-Gly-Thr-His and Gly-Thr-Ser-Met-Ala-Xaa-Pro.
  • Prominent members of family S8, subfamily A are:
  • MEROPS Family name S8 Subfamily A Subtilisin Carlsberg S08.001 Subtilisin lentus S08.003 Thermitase S08.007 Subtilisin BPN' S08.034 Subtilisin DY S08.037 Alkaline peptidase S08.038 Subtilisin ALP 1 S08.045 Subtilisin sendai S08.098 Alkaline elastase YaB S08.157
  • subtilisin related class of serine proteases shares a common amino acid sequence defining a catalytic triad which distinguishes them from the chymotrypsin related class of serine proteases.
  • subtilisin related proteases C
  • subtilisin related proteases C
  • subtilisin herein refers to a serine protease having the catalytic triad of subtilisin related proteases. Examples include the subtilisins as described in WO 89/06276 and EP 0283075, WO 89/06279, WO 89/09830, WO 89/09819, WO 91/06637 and WO 91/02792.
  • Parent proteases of the subtilisin type (EC 3.4.21.62) and variants may be bacterial proteases.
  • Said bacterial protease may be a Gram-positive bacterial polypeptide such as a Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus , or Streptomyces protease, or a Gram-negative bacterial polypeptide such as a Campylobacter, E. coli, Flavobacterium, Fusobacterium, Helicobacter, Ilyobacter, Neisseria, Pseudomonas, Salmonella , or Ureaplasma protease. They act as unspecific endopeptidases, i.e. they hydrolyze any peptide bonds.
  • protease enzymes include those sold under the trade names Alcalase®, Blaze®, DuralaseTM, DuraymTM, Relase®, Relase® Ultra, Savinase®, Savinase® Ultra, Primase®, Polarzyme®, Kannase®, Liquanase®, Liquanase® Ultra, Ovozyme®, Coronase®, Coronase® Ultra, Neutrase®, Everlase® and Esperase® (Novozymes A/S), those sold under the tradename Maxatase®, Maxacal®, Maxapem®, Purafect®, Purafect® Prime, Purafect MA®, Purafect Ox®, Purafect OxP®, Puramax, Properase®, FN2®, FN3®, FN4®, Excellase®, Eraser®, Ultimase®, Opticlean®, Effectenz®, Preferenz® and Optimase (Danisco/DuPont), Ax
  • the parent enzymes and variants may be a Bacillus alcalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus gibsonii, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus sphaericus, Bacillus stearothermophilus, Bacillus subtilis , or Bacillus thuringiensis protease.
  • subtilase is selected from the following:
  • Examples of useful proteases (C) in accordance with the present invention comprise the variants described in: WO 92/19729, WO 95/23221, WO 96/34946, WO 98/20115, WO 98/20116, WO 99/11768, WO 01/44452, WO 02/088340, WO 03/006602, WO 2004/03186, WO 2004/041979, WO 2007/006305, WO 2011/036263, WO 2011/036264, and WO 2011/072099.
  • Suitable examples comprise especially protease variants of subtilisin protease derived from SEQ ID NO:22 as described in EP 1921147 (which is the sequence of mature alkaline protease from Bacillus lentus DSM 5483) with amino acid substitutions in one or more of the following positions: 3, 4, 9, 15, 24, 27, 33, 36, 57, 68, 76, 77, 87, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 118, 120, 123, 128, 129, 130, 131, 154, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252 and 274 (according to the BPN′ numbering), which have proteolytic activity.
  • such a subtilisin protease is not mutated at positions Asp32, His64 and Ser221 (according to BPN
  • subtilisin has SEQ ID NO:22 as described in EP 1921147, or a subtilisin which is at least 80% identical thereto and has proteolytic activity.
  • a subtilisin is at least 80% identical to SEQ ID NO:22 as described in EP 1921147 and is characterized by having amino acid glutamic acid (E), or aspartic acid (D), or asparagine (N), or glutamine (Q), or alanine (A), or glycine (G), or serine (S) at position 101 (according to BPN′ numbering) and has proteolytic activity.
  • subtilisin is at least 80% identical to SEQ ID NO:22 as described in EP 1921147 and is characterized by having amino acid glutamic acid (E), or aspartic acid (D), at position 101 (according to BPN′ numbering) and has proteolytic activity.
  • Such a subtilisin variant may comprise an amino acid substitution at position 101, such as R101E or R101D, alone or in combination with one or more substitutions at positions 3, 4, 9, 15, 24, 27, 33, 36, 57, 68, 76, 77, 87, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 118, 120, 123, 128, 129, 130, 131, 154, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252 and/or 274 (according to BPN′ numbering) and has proteolytic activity.
  • R101E or R101D amino acid substitution at position 101, such as R101E or R101D, alone or in combination with one or more substitutions at positions 3, 4, 9, 15, 24, 27, 33, 36, 57, 68, 76, 77, 87, 95, 96, 97,
  • a subtilisin is at least 80% identical to SEQ ID NO:22 as described in EP 1921147 and is characterized by comprising at least the following amino acids (according to BPN′ numbering) and has proteolytic activity:
  • a subtilisin is at least 80% identical to SEQ ID NO:22 as described in EP 1921147 and is characterized by comprising one amino acid (according to (a)-(h)) or combinations according to (i) together with the amino acid 101E, 101D, 101N, 101Q, 101A, 101G, or 101S (according to BPN′ numbering) and has proteolytic activity.
  • a subtilisin is at least 80% identical to SEQ ID NO:22 as described in EP 1921147 and is characterized by comprising the mutation (according to BPN′ numbering) R101E, or S3T+V4+V205I, or S3T+V4+V199M+V205I+L217D and has proteolytic activity.
  • the subtilisin comprises an amino acid sequence having at least 80% identity to SEQ ID NO:22 as described in EP 1921147 and being further characterized by comprising R101E and S3T, V4I, and V205I (according to the BPN′ numbering) and has proteolytic activity.
  • a subtilisin comprises an amino acid sequence having at least 80% identical to SEQ ID NO:22 as described in EP 1921147 and being further characterized by comprising R101E, and one or more substitutions selected from the group consisting of S156D, L262E, Q137H, S3T, R45E,D,Q, P55N, T58W,Y,L, Q59D,M,N,T, G61 D,R, S87E, G97S, A98D,E,R, S106A,W, N117E, H120V,D,K,N, S125M, P129D, E136Q, S144W, S161T, S163A,G, Y171 L, A172S, N185Q, V199M, Y209W, M222Q, N238H, V244T, N261T,D and L262N,Q,D (as described in WO 2016/096711 and according to the BPN′ numbering), and has proteo
  • subtilisin variant enzymes as disclosed above which are at least n % identical to the respective parent sequences include variants with n being at least 40 to 100.
  • subtilisin variants in one embodiment have proteolytic activity and are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical when compared to the full length polypeptide sequence of the parent enzyme.
  • subtilisin variants comprising conservative mutations not pertaining the functional domain of the respective subtilisin protease.
  • subtilisin variants of this embodiment have proteolytic activity and are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar when compared to the full length polypeptide sequence of the parent enzyme.
  • proteolytic activity or “protease activity” or “proteolytic activity”. This property is related to hydrolytic activity of a protease (proteolysis, which means hydrolysis of peptide bonds linking amino acids together in a polypeptide chain) on protein containing substrates, e.g. casein, hemoglobin and BSA. Quantitatively, proteolytic activity is related to the rate of degradation of protein by a protease or proteolytic enzyme in a defined course of time. The methods for analyzing proteolytic activity are well-known in the literature (see e.g. Gupta et al. (2002), Appl. Microbiol. Biotechnol.
  • Proteolytic activity as such can be determined by using Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Suc-AAPF-pNA, short AAPF; see e.g. DelMar et al. (1979), Analytical Biochem 99, 316-320) as substrate.
  • pNA is cleaved from the substrate molecule by proteolytic cleavage, resulting in release of yellow color of free pNA which can be quantified by measuring OD 405 .
  • Protease variants may have proteolytic activity when said protease variants exhibit at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at 10 least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the proteolytic activity of the respective parent protease.
  • the pI value (isoelectric point) of subtilisin protease used in the present invention is in the range of from pH 7.0 to pH 10.0, preferably from pH 8.0 to pH 9.5.
  • inventive compositions comprise at least one lipase (C).
  • Lipases “Lipases”, “lipolytic enzyme”, “lipid esterase”, all refer to an enzyme of EC class 3.1.1 (“carboxylic ester hydrolase”).
  • Such an enzyme (C) may have lipase activity (or lipolytic activity; triacylglycerol lipase, EC 3.1.1.3), cutinase activity (EC 3.1.1.74; enzymes having cutinase activity may be called cutinase herein), sterol esterase activity (EC 3.1.1.13) and/or wax-ester hydrolase activity (EC 3.1.1.50).
  • Lipases include those of bacterial or fungal origin.
  • lipase examples include but are not limited to those sold under the trade names LipolaseTM, LipexTM, LipolexTM and LipocleanTM (Novozymes A/S), Lumafast (originally from Genencor) and Lipomax (Gist-Brocades/now DSM).
  • a suitable lipase is selected from the following: lipases from Humicola (synonym Thermomyces ), e.g. from H. lanuginosa ( T. lanuginosus ) as described in EP 258068, EP 305216, WO 92/05249 and WO 2009/109500 or from H. insolens as described in WO 96/13580,
  • Suitable lipases (C) also include those referred to as acyltransferases or perhydrolases, e.g. acyltransferases with homology to Candida antarctica lipase A (WO 2010/111143), acyltransferase from Mycobacterium smegmatis (WO 2005/056782), perhydrolases from the CE7 family (WO 2009/67279), and variants of the M. smegmatis perhydrolase in particular the S54V variant (WO 2010/100028).
  • acyltransferases or perhydrolases e.g. acyltransferases with homology to Candida antarctica lipase A (WO 2010/111143), acyltransferase from Mycobacterium smegmatis (WO 2005/056782), perhydrolases from the CE7 family (WO 2009/67279), and variants of the M. smegmatis perhydrolase in particular the S54V variant (
  • Suitable lipases include also those which are variants of the above described lipases and/or cutinases which have lipolytic activity.
  • Such suitable lipase variants are e.g. those which are developed by methods as disclosed in WO 95/22615, WO 97/04079, WO 97/07202, WO 00/60063, WO 2007/087508, EP 407225 and EP 260105.
  • Suitable lipases/cutinases include also those that are variants of the above described lipases/cutinases which have lipolytic activity.
  • Suitable lipase/cutinase variants include variants with at least 40 to 100% identity when compared to the full length polypeptide sequence of the parent enzyme as disclosed above.
  • lipase/cutinase variants having lipolytic activity may be at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical when compared to the full length polypeptide sequence of the parent enzyme as disclosed above.
  • inventive compositions comprise at least one lipase/cutinase variant comprising conservative mutations not pertaining the functional domain of the respective lipase/cutinase.
  • Lipase/cutinase variants of such embodiments having lipolytic activity may be at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% similar when compared to the full length polypeptide sequence of the parent enzyme.
  • Lipases have “lipolytic activity”.
  • the methods for determining lipolytic activity are well-known in the literature (see e.g. Gupta et al. (2003), Biotechnol. Appl. Biochem. 37, p. 63-71).
  • the lipase activity may be measured by ester bond hydrolysis in the substrate para-nitrophenyl palmitate (pNP-Palmitate, C:16) and releases pNP which is yellow and can be detected at 405 nm.
  • Lipase variants may have lipolytic activity according to the present invention when said lipase variants exhibit at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at 10 least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the lipolytic activity of the respective parent lipase.
  • a combination of at least two of the foregoing lipases (C) may be used.
  • Lipase (C) may be used in its non-purified form or in a purified form, e.g. purified with the aid of well-known adsorption methods, such as phenyl sepharose adsorption techniques.
  • lipases (C) are included in inventive composition in such an amount that a finished inventive composition has a lipolytic enzyme activity in the range of from 100 to 0.005 LU/mg, preferably 25 to 0.05 LU/mg of the composition.
  • proteases (C) are included in inventive composition in such an amount that a finished inventive composition has a proteolytic enzyme activity in the range of from 0.1 to 50 GU.
  • lipase (C) and protease (C) in compositions, for example 1 to 2% by weight of protease (C) and 0.1 to 0.5% by weight of lipase (C).
  • an enzyme (C) is called stable when its enzymatic activity “available in application” equals 100% when compared to the initial enzymatic activity before storage.
  • An enzyme may be called stable within this invention if its enzymatic activity available in application is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% when compared to the initial enzymatic activity before storage.
  • lipolytic activity available after storage at 37° C. for 30 days is at least 60% when compared to the initial lipolytic activity before storage.
  • an enzyme is stable according to the invention when essentially no loss of enzymatic activity occurs during storage, i.e. loss in enzymatic activity equals 0% when compared to the initial enzymatic activity before storage.
  • no loss of enzymatic activity within this invention may mean that the loss of enzymatic activity is less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% when compared to the initial enzymatic activity before storage.
  • the loss of lipolytic activity after storage at 37° C. for 30 days is less than 40% when compared to the initial lipolytic activity before storage.
  • Reduced loss of enzymatic activity within this invention may mean that the loss of enzymatic activity is reduced by at least 5%, by at least 10%, by at least 15%, by at least 20%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% when compared to the initial enzymatic activity before storage.
  • salts (A) are used in combination with serine protease inhibitors known per se.
  • serine protease inhibitors are boric acid, a borate, or another boronic acid derivative or a peptide aldehyde.
  • the inhibitor may have an inhibition constant to a serine protease Ki (M, mol/L) of 1E-12-1E-03; more preferred 1E-11-1E-04; even more preferred: 1E-10-1E-05; even more preferred 1E-10-1E-06; most preferred 1E-09-1E-07.
  • salt (A) in inventive formulations without boron based inhibitors.
  • inventive compositions are preferably used as detergent compositions. It is possible, though, to use inventive compositions in further fields, for example in the manufacture of leather.
  • enzyme (C) and preferably lipase (C) may be present in an amount of 0.01 to 4.0% by weight, preferred are 0.1 to 1.5% by weight.
  • a weight ratio of salt (A):lipase (C) in the range of from 0.5:1 to 50:1 is preferred, more preferred from 5:1 to 20:1 and even more preferred 5:1 to 10:1.
  • ingredients in a non-detergent liquid compositions may be selected from polyols and mixtures of polyols, for example sorbitol, glycerol, and propylene glycol, each in amounts of 1 to 60%, small amounts of non-ionic surfactants (ex softanol) 0-5%, calcium ions 0.001%-0.5%, water. Further examples are preservatives, e.g., 2-phenoxyethanol.
  • compositions may contain one or more ingredients other than salt (A), surfactant (B) or enzyme (C), for example organic solvents, fragrances, dyestuffs, biocides, preservatives, hydrotropes, builders, viscosity modifiers, polymers, buffers, defoamers, and anti-corrosion additives.
  • ingredients other than salt (A), surfactant (B) or enzyme (C) for example organic solvents, fragrances, dyestuffs, biocides, preservatives, hydrotropes, builders, viscosity modifiers, polymers, buffers, defoamers, and anti-corrosion additives.
  • compositions according to the present invention may comprise one or more organic solvents, for example ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol, sec.-butanol, ethylene glycol, propylene glycol, 1,3-propane diol, butane diol, glycerol, diglycol, propyl diglycol, butyl diglycol, hexylene glycol, ethylene glycol methyl ether, ethylene glycol ethyl ether, ethylene glycol propyl ether, and phenoxyethanol, preferred are ethanol, isopropanol or propylene glycol.
  • Preferred amounts of organic solvents are 0.5 to 25% by weight, referring to the entire inventive composition. Especially when inventive compositions are delivered in pouches or the like, 8 to 25% by weight of organic solvent(s).
  • fragrances are benzyl salicylate, 2-(4-tert.-butylphenyl) 2-methylpropional, commercially available as Lilial®, and hexyl cinnamaldehyde.
  • dyestuffs are Acid Blue 9, Acid Yellow 3, Acid Yellow 23, Acid Yellow 73, Pigment Yellow 101, Acid Green 1, Solvent Green 7, and Acid Green 25.
  • Inventive liquid detergent compositions may contain one or more preservatives or biocides.
  • Biocides and preservatives prevent alterations of inventive liquid detergent compositions due to attacks from microorganisms.
  • examples of biocides and preservatives are BTA (1,2,3-benzotriazole), benzalkonium chlorides, 1,2-benzisothiazolin-3-one (“BIT”), 2-methyl-2H-isothiazol-3-one (“MIT”) and 5-chloro-2-methyl-2H-isothiazol-3-one (“CIT”), benzoic acid, sorbic acid, iodopropynyl butylcarbamate (“IPBC”), dichlorodimethylhydantoine (“DCDMH”), bromochlorodimethylhydantoine (“BCDMH”), and dibromodimethylhydantoine (“DBDMH”).
  • BTA 1,2-benzisothiazolin-3-one
  • MIT 2-methyl-2H-isothiazol-3
  • viscosity modifiers examples include agar-agar, carragene, tragacanth, gum arabic, alginates, pectins, hydroxyethyl cellulose, hydroxypropyl cellulose, starch, gelatin, locust bean gum, cross-linked poly(meth)acrlyates, for example polyacrlyic acid cross-linked with bis-(meth)acrylamide, furthermore silicic acid, clay such as—but not limited to—montmorrilionite, zeolite, dextrin, and casein.
  • Hydrotropes in the context with the present invention are compounds that facilitate the dissolution of compounds that exhibit limited solubilty in water.
  • hydrotropes are organic solvents such as ethanol, isopropanol, ethylene glycol, 1,2-propylene glycol, and further organic solvents that are water-miscible under normal conditions without limitation.
  • suitable hydrotropes are the sodium salts of toluene sulfonic acid, of xylene sulfonic acid, and of cumene sulfonic acid.
  • polymers are especially polyacrylic acid and its respective alkali metal salts, especially its sodium salt.
  • a suitable polymer is in particular polyacrylic acid, preferably with an average molecular weight M w in the range from 2,000 to 40,000 g/mol. preferably 2,000 to 10,000 g/mol, in particular 3,000 to 8,000 g/mol, each partially or fully neutralized with alkali, especially with sodium.
  • copolymeric polycarboxylates in particular those of acrylic acid with methacrylic acid and of acrylic acid or methacrylic acid with maleic acid and/or fumaric acid.
  • Polyacrylic acid and its respective alkali metal salts may serve as soil anti-redeposition agents.
  • polymers are polyvinylpyrrolidones (PVP).
  • PVP polyvinylpyrrolidones
  • Polyvinylpyrrolidones may serve as dye transfer inhibitors.
  • polymers are polyethylene terephthalates, polyoxyethylene terphthalates, and polyethylene terephthalates that are end-capped with one or two hydrophilic groups per molecule, hydrophilic groups being selected from CH 2 CH 2 CH 2 —SO 3 Na, CH 2 CH(CH 2 —SO 3 Na) 2 , and CH 2 CH(CH 2 SO 2 Na)CH 2 —SO 3 Na.
  • buffers are monoethanolamine and N,N,N-triethanolamine.
  • defoamers are silicones.
  • inventive compositions may contain one or more builders other than salt (A).
  • compositions may contain 1 to 40% by weight of a detergent builder other than salt (A), such as, but not limited to zeolite, phosphate, phosphonate, citrate, polymer builders, or aminocarboxylates such as the alkali metal salts of iminodisuccinates, for example IDS-Na 4 , furthermore nitrilotriacetic acid (“NTA”), methylglycine diacetic acid (“MGDA”), glutamic acid diacetic acid (“GLDA”), ethylene diamine tetraacetic acid (“EDTA”) or diethylenetriamine pentaacetic acid (“DTPA”).
  • a detergent builder other than salt such as, but not limited to zeolite, phosphate, phosphonate, citrate, polymer builders, or aminocarboxylates such as the alkali metal salts of iminodisuccinates, for example IDS-Na 4 , furthermore nitrilotriacetic acid (“NTA”), methylgly
  • detergent builders are polymers with complexing groups like, for example, polyethylenimine in which 20 to 90 mole-% of the N-atoms bear at least one CH 2 COO ⁇ group, and the respective alkali metal salts of the above sequestrants, especially their sodium salts.
  • polyalkylenimines for example polyethylenimines and polypropylene imines.
  • Polyalkylenimines may be used as such or as polyalkoxylated derivatives, for examples ethoxylated or propoxylated.
  • Polyalkylenimines contain at least three alkylenimine units per molecule.
  • said alkylenimine unit is a C 2 -C 10 -alkylendiamine unit, for example a 1,2-propylendiamine, preferably an ⁇ , ⁇ -C 2 -C 10 -alkylendiamine, for example 1,2-ethylendiamine, 1,3-propylendiamine, 1,4-butylendiamine, 1,5-pentylendiaminne, 1,6-hexandiamine (also being referred to as 1,6-hexylendiamine), 1,8-diamine or 1,10-decandiamine, even more preferred are 1,2-ethylendiamine, 1,3-propylendiamine, 1,4-butylendiamine, and 1,6-hexandiamine.
  • 1,2-propylendiamine preferably an ⁇ , ⁇ -C 2 -C 10 -alkylendiamine
  • ⁇ , ⁇ -C 2 -C 10 -alkylendiamine for example 1,2-ethylendiamine
  • said polyalkylenimine is selected from polyalkylenimine unit, preferably a polyethylenimine or polypropylenimine unit.
  • polyethylenimine in the context of the present invention does not only refer to polyethylenimine homopolymers but also to polyalkylenimines containing NH—CH 2 —CH 2 —NH structural elements together with other alkylene diamine structural elements, for example NH—CH 2 —CH 2 —CH 2 —NH structural elements, NH—CH 2 —CH(CH 3 )—NH structural elements, NH—(CH 2 ) 4 —NH structural elements, NH—(CH 2 )—NH structural elements or (NH—(CH 2 )—NH structural elements but the NH—CH 2 —CH 2 —NH structural elements being in the majority with respect to the molar share.
  • Preferred polyethylenimines contain NH—CH 2 —CH 2 —NH structural elements being in the majority with respect to the molar share, for example amounting to 60 mol-% or more, more preferably amounting to at least 70 mol-%, referring to all alkylenimine structural elements.
  • polyethylenimine refers to those polyalkylenimines that bear only one or zero alkylenimine structural element per polyethylenimine unit that is different from NH—CH 2 —CH 2 —NH.
  • polypropylenimine in the context of the present invention does not only refer to polypropylenimine homopolymers but also to polyalkylenimines containing NH—CH 2 —CH(CH 3 )—NH structural elements together with other alkylene diamine structural elements, for example NH—CH 2 —CH 2 —CH 2 —NH structural elements, NH—CH 2 —CH 2 —NH structural elements, NH—(CH 2 ) 4 —NH structural elements, NH—(CH 2 ) 6 —NH structural elements or (NH—(CH 2 ) 8 —NH structural elements but the NH—CH 2 —CH(CH 3 )—NH structural elements being in the majority with respect to the molar share.
  • Preferred polypropylenimines contain NH—CH 2 —CH(CH 3 )—NH structural elements being in the majority with respect to the molar share, for example amounting to 60 mol-% or more, more preferably amounting to at least 70 mol-%, referring to all alkylenimine structural elements.
  • polypropylenimine refers to those polyalkylenimines that bear only one or zero alkylenimine structural element per polypropylenimine unit that is different from NH—CH 2 —CH(CH 3 )—NH.
  • Branches may be alkylenamino groups such as, but not limited to —CH 2 —CH 2 —NH 2 groups or (CH 2 )—NH 2 -groups.
  • Longer branches may be, for examples, —(CH 2 ) 3 —N(CH 2 CH 2 CH 2 NH 2 ) 2 or —(CH 2 ) 2 —N(CH 2 CH 2 NH 2 ) 2 groups.
  • Highly branched polyethylenimines are, e.g., polyethylenimine dendrimers or related molecules with a degree of branching in the range from 0.25 to 0.95, preferably in the range from 0.30 to 0.80 and particularly preferably at least 0.5.
  • the degree of branching can be determined for example by 13 C-NMR or 15 N-NMR spectroscopy, preferably in D 2 O, and is defined as follows:
  • D dendritic
  • L linear
  • T terminal
  • branched polyethylenimine units are polyethylenimine units with DB in the range from 0.25 to 0.95, particularly preferably in the range from 0.30 to 0.90% and very particularly preferably at least 0.5.
  • Preferred polyethylenimine units are those that exhibit little or no branching, thus predominantly linear or linear polyethylenimine units.
  • CH 3 -groups are not being considered as branches.
  • polyalkylenimine may have a primary amine value in the range of from 1 to 1000 mg KOH/g, preferably from 10 to 500 mg KOH/g, most preferred from 50 to 300 mg KOH/g.
  • the primary amine value can be determined according to ASTM D2074-07.
  • polyalkylenimine may have a secondary amine value in the range of from 10 to 1000 mg KOH/g, preferably from 50 to 500 mg KOH/g, most preferred from 50 to 500 mg KOH/g.
  • the secondary amine value can be determined according to ASTM D2074-07.
  • polyalkylenimine may have a tertiary amine value in the range of from 1 to 300 mg KOH/g, preferably from 5 to 200 mg KOH/g, most preferred from 10 to 100 mg KOH/g.
  • the tertiary amine value can be determined according to ASTM D2074-07.
  • the molar share of tertiary N atoms is determined by 15 N-NMR spectroscopy. In cases that tertiary amine value and result according to 13 C-NMR spectroscopy are inconsistent, the results obtained by 13 C-NMR spectroscopy will be given preference.
  • the average molecular weight M w of said polyalkylenimine is in the range of from 250 to 100,000 g/mol, preferably up to 50,000 g/mol and more preferably from 800 up to 25,000 g/mol.
  • the average molecular weight M w of polyalkylenimine may be determined by gel permeation chromatography (GPC) of the intermediate respective polyalkylenimine, with 1.5% by weight aqueous formic acid as eluent and cross-linked polyhydroxyethyl methacrylate as stationary phase.
  • Said polyalkylenimine may be free or alkoxylated, said alkoxylation being selected from ethoxylation, propoxylation, butoxylation and combinations of at least two of the foregoing. Preference is given to ethylene oxide, 1,2-propylene oxide and mixtures of ethylene oxide and 1,2-propylene oxide. If mixtures of at least two alkylene oxides are applied, they can be reacted step-wise or simultaneously.
  • an alkoxylated polyalkylenimine bears at least 6 nitrogen atoms per unit.
  • polyalkylenimine is alkoxylated with 2 to 50 moles of alkylene oxide per NH group, preferably 5 to 30 moles of alkylene oxide per NH group, even more preferred 5 to 25 moles of ethylene oxide or 1,2-propylene oxide or combinations therefrom per NH group.
  • an NH 2 unit is counted as two NH groups.
  • all—or almost all—NH groups are alkoxylated, and there are no detectable amounts of NH groups left.
  • the molecular weight distribution may be narrow or broad.
  • the polydispersity Q M w /M n in the range of from 1 to 3, preferably at least 1.2 and more preferably 1.2 to 2.5, or it may as well be greater than 3 and up to 20, for example 3.5 to 15 and—in case of broad molecular weight distributions—more preferred in the range of from 4 to 5.5.
  • the polydispersity Q of alkoxylated polyalkylenimine is in the range of from 2 to 10.
  • alkoxylated polyalkylenimine is selected from polyethoxylated polyethylenimine, ethoxylated polypropylenimine, ethoxylated ⁇ , ⁇ -hexandiamines, ethoxylated and propoxylated polyethylenimine, ethoxylated and propoxylated polypropylenimine, and ethoxylated and poly-propoxylated ⁇ , ⁇ -hexandiamines.
  • the average molecular weight Mn (number average) of alkoxylated polyethylenimine is in the range of from 2,500 to 1,500,000 g/mol, determined by GPC, preferably up to 500,000 g/mol.
  • the average alkoxylated polyalkylenimine are selected from ethoxylated ⁇ , ⁇ -hexanediamines and ethoxylated and poly-propoxylated ⁇ , ⁇ -hexanediamines, each with an average molecular weight Mn (number average) in the range of from 800 to 50,000 g/mol.
  • inventive compositions are unbuilt, i.e. essentially free of additional detergent builder.
  • inventive liquid compositions may comprise from about 0.1% to about 15%, more particularly from 0.25% to 10%, and most particularly from about 0.5% to 5% of salt (A).
  • a stabilized liquid enzyme formulation may contain 0.5 to 20% by weight, particularly 1-10% by weight, of enzyme (C) (total of protease and optional second enzyme) and 0.01% to 10% of salt (A), more particularly 0.05 to 5% by weight and most particularly 0.1% to 2% by weight of salt (A).
  • Succinate builders are preferably used in the form of their water-soluble salts, including the sodium, potassium. ammonium and alkanolammonium salts.
  • Specific examples of succinate builders include: laurylsuccinate, myristylsuccinate, palmitylsuccinate, 2-dodecenylsuccinat (preferred), 2-pentadecenylsuccinate, and the like. Laurylsuccinates are the preferred builders of the above group.
  • compositions allow a flexible formulation, even with high or low water content. It was further the objective to provide a composition that has excellent shelf life, especially with respect to the enzyme(s) contained therein. Inventive compositions are therefore excellently suited for laundering of fabrics. Therefore, a further aspect of the present invention is directed towards the use of inventive compositions for the laundering of fabrics. In particular, liquid inventive formulations are excellently suited for laundering of fabrics.
  • Inventive detergent compositions may be used as fabric cleaning compositions, hard surface cleansing compositions, light duty cleaning compositions including dish cleansing compositions and automatic dishwasher detergent compositions.
  • a further aspect of the present invention is directed towards the use of a salt (A) for the stabilization of enzymes.
  • Salts (A) have been defined in more details above.
  • a further aspect of the present invention is a process for making inventive compositions, hereinafter also referred to as inventive manufacturing process.
  • inventive manufacturing process comprises the steps of
  • Steps (a) and (b) may be performed in any order. However, in embodiments wherein surfactant (B) may lead to foam formation it is preferred to first mix salt (A) and enzyme (C) and to then add surfactant (B).
  • Mixing of salt (A) and enzyme (C) may be performed in any type of vessel. Preferably, foaming and high shear rates during mixing are avoided. Preferred devices are tubular mixers and static mixers.
  • salt (A) is a compound of general formula (I)
  • n is selected from 1 to 12,
  • n is selected from zero to 50
  • R 1 is selected from C 1 -C 10 -alkyl, linear or branched, and C 6 -C 10 -aryl, wherein R 1 may bear one or more hydroxyl or C ⁇ O or COOH groups, partially or fully neutralized, if applicable,
  • R 2 are same or different and selected from C 1 -C 10 -alkyl, phenyl,
  • R 3 and R 4 are same or different and selected from hydrogen and C 1 -C 4 -alkyl
  • X is C 2 -C 4 -alkylen
  • a ⁇ is a counteranion, inorganic or organic.
  • the variables R 1 , R 2 , m, n and A ⁇ are as defined above.
  • R 2 in compound according to general formula (I) are all methyl.
  • salt (A) has a counterion selected from halide, sulphate, carbonate, tartrate, citrate, lactate, and methanesulfonate.
  • the at least on enzyme (C) is selected from protease, amylase, and lipase.
  • Weight % of enzymes refer to the enzyme preparation as used and available commercially—the weight % of pure protein is quite lower—hence the turn over number/mg as described is important.
  • Acetylcholine (A.12) was purchased from Sigma Aldrich. The counterion was chloride.
  • the precursor of (A.14) can be produced directly instead of use of HCl in the ethoxylation of trimethylamine or via reaction of choline hydrogencarbonate with methanesulfonic, see Constantinescu et al in Chem. Eng. Data, 2007, 521280-1285.
  • 90% methanesulfonic acid refers to a mixture from 10% water and 90% methanesulfonic acid.
  • a light yellowish substance was obtained that was diluted with 200 g diethylene glycol. An amount of 607 g of a yellowish liquid were obtained. An aliquot of 200 g of the liquid so obtained was neutralized with 8.7 g ethanolamine to a pH value of 6 to 6.5 (10% in water). Inventive salt (A.2) was obtained.
  • citric acid monohydrate 1.0 mol
  • a 75% by weight aqueous solution of choline methanesulfonate 2.0 mol.
  • Water was removed within 45 minutes in a rotary evaporator (2-l-flask)—oil bath temperature of 100 to 120° C., 50 to 80 mbar.
  • citric acid monohydrate 1.0 mole was dissolved in 437 g of a 70% by weight aqueous solution of beta-methyl choline chloride (HO—CH(CH 3 —CH 2 —N(CH 3 ) 3 Cl, 2.0 moles).
  • Water was removed within 45 minutes in a rotary evaporator (2-l-flask)—oil bath temperature of 100 to 120° C., 50 to 80 mbar.
  • An amount of 18 g of 90% by weight methanesulfonic acid were added and the temperature was raised to 145° C. at a pressure of 800 mbar. After one hour of rotary evaporation the pressure was continuously reduced to 10 mbar while water was removed for another 4.5 h at 145° C.
  • a light yellowish substance was obtained that was diluted with 200 g diethylene glycol. An amount of 676 g of a yellowish liquid was obtained. An aliquot of 200 g of the liquid so obtained was neutralized with 12.3 g ethanolamine to a pH value of 6 to 6.5 (10% in water). Inventive salt (A.7) was obtained.
  • a light yellowish substance was obtained that was diluted with 170 g diethylene glycol. An amount of 471 g of a yellowish liquid was obtained. An aliquot of 200 g of the liquid so obtained was neutralized with 21.7 g triethanolamine to a pH value of 6 to 6.5 (10% in water). Inventive salt (A.8) was obtained.
  • a light yellowish substance was obtained that was diluted with 250 g propylene glycol. An amount of 774 g of a yellowish liquid was obtained. An aliquot of 200 g of the liquid so obtained was neutralized with 11.9 g ethanolamine to a pH value of 6 to 6.5 (10% in water). Inventive salt (A.9) was obtained.
  • citric acid monohydrate 0.5 moles was dissolved in 397 g of a 60% by weight aqueous solution of dimethyl n-octylcholine chloride (1.0 mole).
  • Water was removed within 90 minutes in a rotary evaporator (2-l-flask)—oil bath temperature of 100 to 120° C., 50 to 80 mbar.
  • An amount of 9.5 g of 90% methanesulfonic acid was added and the temperature was raised to 145° C. at a pressure of 800 mbar. After one hour of rotary evaporation the pressure was continuously reduced to 10 mbar while water was removed for another 4.5 h at 145° C.
  • a light yellowish substance was obtained that was diluted with 200 g propylene glycol. An amount of 470 g of a yellowish liquid was obtained. An aliquot of 200 g of the liquid so obtained was neutralized with 8.9 g ethanolamine to a pH value of 6 to 6.5 (10% in water). Inventive salt (A.11) was obtained.
  • gallic acid (3,4,5-trihydroxybenzoic-acid, 0.5 moles) was dispersed in 121 g of a 75% by weight aqueous solution of choline methanesulfonate (0.5 moles).
  • Water was removed within 90 minutes in a rotary evaporator (2-l-flask)—oil bath temperature of 100 to 120° C., 50 to 80 mbar.
  • An amount of 8 g of 90% methanesulfonic acid was added and the temperature was raised to 145° C. at a pressure of 800 mbar. After one hour of rotary evaporation the pressure was continuously reduced to 10 mbar while water was removed for another 4.5 h at 145° C.
  • a light yellowish substance was obtained that was diluted with 100 g diethylene glycol. An amount of 271 g of a yellowish liquid was obtained. An aliquot of 100 g of the liquid so obtained was neutralized with 4.6 g ethanolamine to a pH value of 6 to 6.5 (10% in water). Inventive salt (A.13) was obtained.
  • C-(A.17) An amount of 105 g (0.5 mol) citric acid monohydrate was portion-wise dissolved (20 g units) in 206 g of an 80% by weight aqueous solution of choline bicarbonate (1.0 mol). The solution was stirred until the CO 2 evolution ceased. Water was removed within 90 minutes by rotary evaporation (2-l-flask)—oil bath temperature of 120° C., 10 mbar. A clear substance was obtained that was diluted with 150 g diethylene glycol. 412 g of a clear solution were obtained, C-(A.17). No ester formation could be detected.
  • C-(A.18) An amount of 105 g (0.5 mol) citric acid monohydrate was portion-wise dissolved (20 g units) in 309 g of an 80% by weight aqueous solution of choline bicarbonate (1.5 moles). The solution was stirred until the CO 2 evolution ceased. Water was removed within 90 minutes by rotary evaporation (2-l-flask)—oil bath temperature of 120° C., 10 mbar. A clear substance was obtained that was diluted with 150 g diethylene glycol. 497 g of a clear viscous solution were obtained, C-(A.18). No ester formation could be detected.
  • C-(A.19) citric acid monohydrate
  • C-(A.20) monosodium salt of citric acid
  • C-(A.21) disodium salt of citric acid
  • C-(A.22) trisodium salt of citric acid.
  • C-(A.19), C-(A.20), C-(A.21) and C-(A.22) are known builder compounds used in detergents formulations.
  • Salts (A.1) to (A.11) and C-(A.16) to C-(A.18) are each soluble in diethylene glycol and/or dipropylene glycol and hence can be formulated without water.
  • Base test formulations were manufactured by making base formulations I to VI by mixing the components according to Table 1.
  • the respective salt (A) or comparative compound was added, if applicable, to the respective base formulation in amounts as indicated in Table 1.
  • Enzyme (C) was added, to the respective base formulation in amounts as indicated in Table 1.
  • the amount of enzyme as provided in Table 1 refers to active protein. Either lipase or protease was added, depending on which enzyme activity was measured.
  • Lipolase® 100 L (CAS-No. 9001-62-1, EC-No. 232-619-9) was purchased from Sigma-Aldrich.
  • Savinase® 16.0 L (CAS-No. 9014-01-1, EC-No. 232-752-2) was purchased from Sigma-Aldrich.
  • Lipolase activity at certain points in time as indicated in Table 2 was be determined by employing pNitrophenol-valerate (2.4 mM pNP-C5 in 100 mM Tris pH 8.0, 0.01% Triton X100) as a substrate. The absorption was measured at 20° C. every 30 seconds over 5 minutes at 405 nm.
  • the slope (absorbance increase at 405 nm per minute) of the time dependent absorption-curve is directly proportional to the activity of the lipase.
  • Table 2 shows lipase activity in liquid formulations measured after storage; 1-30 days at 37° C.
  • the lipolytic activity values provided in Table 2 were calculated referring to the 100% value determined in the reference formulation at the time 0.
  • the enzyme activity of the protease was measured in a Thermo Fisher Scientific Gallery one-channel interference filter photometer (made by Thermo Fisher Scientific) by titration with N-succinyl-Ala-Ala-Pro-Phe-p-pitroanilide in DMSO.
  • the release of para-nitroaniline resulted in an increase of absorbance at 405 nm and is proportional to the enzyme activity measured in PROT units.
  • One PROT is the amount of enzyme that releases 1 ⁇ mol of para-nitroaniline from I mM of N-succinyl-Ala-Ala-Pro-Phe-p-pitroanilide per minute at pH of 9.0 and 37° C.
  • lipase activity in formulations and comparative formulations was determined after storage; 1-30 days at 37° C. An activity of 100% refers to the activity in aqueous environment and identical concentration.
  • pNA is cleaved from the substrate molecule by proteolytic cleavage, resulting in release of yellow color of free pNA which was determined by measuring OD 405 . Measurement were done at 20° C.
  • Table 3 displays protease activity measured in liquid formulations after storage for 1 to 30 days at 37° C. The proteolytic activity values provided in Table 3 were calculated referring to the 100% value determined in the reference formulation at the time 0.
  • the nomenclature of formulations is as follows: the Roman number before the full stop characterizes the base formulation, the Arabian number the type of salt (A.# inventive salt (component (a)); C-(A.#) comparative compound). Zero (“0”): no salt, but diethylene glycol.
  • testing cloth samples comprised a complex soil containing proteinaceous and fatty components due to CFT process as well as test cloth samples contained a fatty/particulate type of soil.
  • test was performed as follows: a multi stain monitor containing 8 standardized soiled fabric patches, each of 2.5 ⁇ 2.5 cm size and stitched on two sides to a polyester carrier was washed together in a launder-O-meter with 2.5 g of cotton fabric and 5 g/L of the liquid test laundry detergent, Table 4.
  • washing liquor 250 ml, washing time: 60 minutes, washing temperature: 30° C.
  • Water hardness 2.5 mmol/L; Ca:Mg:HCO 3 4:1:8
  • wfk20D pigment and sebum-type fat on polyester/cotton mixed fabric
  • the total level of cleaning was evaluated using color measurements. Reflectance values of the stains on the monitors were measured using a sphere reflectance spectrometer (SF 500 type from Datacolor, USA, wavelength range 360-700 nm, optical geometry d/8°) with a UV cutoff filter at 460 nm. In this case, with the aid of the CIE-Lab color space classification, the brightness L*, the value a* on the red-green color axis and the b* value on the yellow-blue color axis, were measured before and after washing and averaged for the 8 stains of the monitor.
  • the change of the color value (A E) value defined and calculated automatically by the evaluation color tools on the following equation:
  • ⁇ E is a measure of the achieved cleaning effect. All measurements were repeated six times to yield an average number. Note that higher A E values show better cleaning. A difference of 1 unit can be detected by a skilled person. A non-expert can detect 2 units easily. The results are shown in Table 5
  • the increase in detergency due to the builder was calculated as: A total of 6 replications of each cloth were run during this study; a statistical confidence level of 90-95% was calculated.
  • Test formulations were manufactured by making formulations VII to XIII by mixing the components according to Table 4.
  • the respective salt (A) or comparative compound was added, if applicable, to the respective base formulation in amounts provided in Table 4.
  • Lipolase® 100 L was added, if applicable, to the respective base formulation in amounts provided in Table 4.
  • Table 5 shows the sum of ⁇ E of the above mentioned multi-stain monitor.
  • the launder-O-meter tests were executed with freshly prepared formulation (to) and with storing at 37° C. during a 2-month storage temperature. As an approximation one week at 37° C. is equivalent to 31 ⁇ 2 weeks at 20° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
US16/763,430 2017-11-29 2018-11-19 Compositions, their manufacture and use Abandoned US20210071118A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17204358.0 2017-11-29
EP17204357 2017-11-29
EP17204357.2 2017-11-29
EP17204358 2017-11-29
PCT/EP2018/081699 WO2019105780A1 (en) 2017-11-29 2018-11-19 Compositions, their manufacture and use

Publications (1)

Publication Number Publication Date
US20210071118A1 true US20210071118A1 (en) 2021-03-11

Family

ID=64308770

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/763,430 Abandoned US20210071118A1 (en) 2017-11-29 2018-11-19 Compositions, their manufacture and use
US16/768,109 Active 2039-04-27 US11512268B2 (en) 2017-11-29 2018-11-19 Storage-stable enzyme preparations, their production and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/768,109 Active 2039-04-27 US11512268B2 (en) 2017-11-29 2018-11-19 Storage-stable enzyme preparations, their production and use

Country Status (9)

Country Link
US (2) US20210071118A1 (ko)
EP (2) EP3717612A1 (ko)
JP (2) JP2021504546A (ko)
KR (1) KR20200088433A (ko)
CN (2) CN111417707A (ko)
BR (2) BR112020008695A2 (ko)
CA (1) CA3083390A1 (ko)
MX (1) MX2020005661A (ko)
WO (2) WO2019105780A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291334A1 (en) * 2017-11-29 2020-09-17 Basf Se Storage-stable enzyme preparations, their production and use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022131339A1 (ja) * 2020-12-16 2022-06-23 ライオン株式会社 液体洗浄剤

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234445A (ko) 1967-10-03 1971-06-03
BE793339A (fr) * 1970-10-20 1973-06-27 Henkel & Cie Gmbh Agent de traitement complementaire du linge et son procede de preparation
GB1372034A (en) 1970-12-31 1974-10-30 Unilever Ltd Detergent compositions
DE2848892A1 (de) * 1977-11-16 1979-05-17 Unilever Nv Waescheweichspuelmittel
ATE13554T1 (de) * 1980-11-06 1985-06-15 Procter & Gamble Reinigungsmittelzusammensetzungen.
US4465619A (en) 1981-11-13 1984-08-14 Lever Brothers Company Built liquid detergent compositions
US5185258A (en) 1984-05-29 1993-02-09 Genencor International, Inc. Subtilisin mutants
JPH0697997B2 (ja) 1985-08-09 1994-12-07 ギスト ブロカデス ナ−ムロ−ゼ フエンノ−トチヤツプ 新規の酵素的洗浄剤添加物
US5013657A (en) 1988-04-12 1991-05-07 Bryan Philip N Subtilisin mutations
US4990452A (en) 1986-02-12 1991-02-05 Genex Corporation Combining mutations for stabilization of subtilisin
DE3750450T2 (de) 1986-08-29 1995-01-05 Novo Industri As Enzymhaltiger Reinigungsmittelzusatz.
NZ221627A (en) 1986-09-09 1993-04-28 Genencor Inc Preparation of enzymes, modifications, catalytic triads to alter ratios or transesterification/hydrolysis ratios
US5389536A (en) 1986-11-19 1995-02-14 Genencor, Inc. Lipase from Pseudomonas mendocina having cutinase activity
EP0896062A3 (en) 1987-02-27 1999-04-07 Genencor International, Inc. Transformation of alkalophilic bacillus strains
DE3851875T2 (de) 1987-05-29 1995-04-13 Genencor Int Cutinase haltige reinigungsmittelzusammensetzungen.
ATE125865T1 (de) 1987-08-28 1995-08-15 Novo Nordisk As Rekombinante humicola-lipase und verfahren zur herstellung von rekombinanten humicola-lipasen.
JPS6474992A (en) 1987-09-16 1989-03-20 Fuji Oil Co Ltd Dna sequence, plasmid and production of lipase
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
EP0327801A1 (en) 1988-01-08 1989-08-16 Deutsches Primatenzentrum Gesellschaft Mbh HIV-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
JP3079276B2 (ja) 1988-02-28 2000-08-21 天野製薬株式会社 組換え体ｄｎａ、それを含むシュードモナス属菌及びそれを用いたリパーゼの製造法
WO1990009446A1 (en) 1989-02-17 1990-08-23 Plant Genetic Systems N.V. Cutinase
GB8915658D0 (en) 1989-07-07 1989-08-23 Unilever Plc Enzymes,their production and use
DK0493398T3 (da) 1989-08-25 2000-05-22 Henkel Research Corp Alkalisk, proteolytisk enzym og fremgangsmåde til fremstilling deraf
US5427936A (en) 1990-04-14 1995-06-27 Kali-Chemie Aktiengesellschaft Alkaline bacillus lipases, coding DNA sequences therefor and bacilli, which produce these lipases
US5073292A (en) * 1990-06-07 1991-12-17 Lever Brothers Company, Division Of Conopco, Inc. Heavy duty liquid detergent compositions containing enzymes stabilized by quaternary nitrogen substituted proteins
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
AU657278B2 (en) 1990-09-13 1995-03-09 Novo Nordisk A/S Lipase variants
EP0478050A1 (en) 1990-09-24 1992-04-01 Unilever N.V. Detergent composition
ES2121014T3 (es) 1991-05-01 1998-11-16 Novo Nordisk As Enzimas estabilizadas y composiciones detergentes.
DK88892D0 (da) 1992-07-06 1992-07-06 Novo Nordisk As Forbindelse
ATE287946T1 (de) 1993-04-27 2005-02-15 Genencor Int Neuartige lipasevarianten zur verwendung in reinigungsmitteln
EP0634485B1 (en) * 1993-07-14 2001-09-05 The Procter & Gamble Company Detergent-package combination
JP2859520B2 (ja) 1993-08-30 1999-02-17 ノボ ノルディスク アクティーゼルスカブ リパーゼ及びそれを生産する微生物及びリパーゼ製造方法及びリパーゼ含有洗剤組成物
JPH09503916A (ja) 1993-10-08 1997-04-22 ノボ ノルディスク アクティーゼルスカブ アミラーゼ変異体
JPH07143883A (ja) 1993-11-24 1995-06-06 Showa Denko Kk リパーゼ遺伝子及び変異体リパーゼ
MX9603542A (es) 1994-02-22 1997-03-29 Novo Nordisk As Metodo para preparar una variante de una enzima lipolitica.
DE69535736T2 (de) 1994-02-24 2009-04-30 Henkel Ag & Co. Kgaa Verbesserte enzyme und diese enthaltene detergentien
US6017866A (en) 1994-05-04 2000-01-25 Genencor International, Inc. Lipases with improved surfactant resistance
WO1995033033A1 (en) 1994-06-01 1995-12-07 The Procter & Gamble Company Laundry detergent compositions
AU2884595A (en) 1994-06-20 1996-01-15 Unilever Plc Modified pseudomonas lipases and their use
WO1996000292A1 (en) 1994-06-23 1996-01-04 Unilever N.V. Modified pseudomonas lipases and their use
BE1008998A3 (fr) 1994-10-14 1996-10-01 Solvay Lipase, microorganisme la produisant, procede de preparation de cette lipase et utilisations de celle-ci.
CA2203398A1 (en) 1994-10-26 1996-05-09 Thomas Sandal An enzyme with lipolytic activity
EP0709449A1 (en) * 1994-10-28 1996-05-01 The Procter & Gamble Company Non-aqueous compositions comprising polyhydroxy fatty acid amides
WO1996023872A1 (en) 1995-02-02 1996-08-08 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Enrichment of hematopoietic stem cells from blood or bone marrow
JPH08228778A (ja) 1995-02-27 1996-09-10 Showa Denko Kk 新規なリパーゼ遺伝子及びそれを用いたリパーゼの製造方法
AU5644896A (en) 1995-05-05 1996-11-21 Novo Nordisk A/S Protease variants and compositions
GB9513999D0 (en) 1995-07-08 1995-09-06 Procter & Gamble Detergent compositions
US6008178A (en) * 1995-07-08 1999-12-28 Procter & Gamble Company Detergent composition comprising cationic ester surfactant and protease enzyme
WO1997007202A1 (en) 1995-08-11 1997-02-27 Novo Nordisk A/S Novel lipolytic enzymes
AU6414196A (en) 1995-07-14 1997-02-18 Novo Nordisk A/S A modified enzyme with lipolytic activity
CA2266527A1 (en) 1996-09-24 1998-04-02 John Mcmillan Mciver Liquid detergents containing proteolytic enzyme, peptide aldehyde and calcium ions
WO1998020115A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
BR9712878A (pt) 1996-11-04 2000-02-01 Novo Nordisk As Variante de enzima subtilase, processos para a identificação de uma variante de protease apresentando estabilidade autoproteolìtica e paraq a produção de uma enzima subtilase mutante e de uma variante de subtilase, sequência de dna, vetor, célula hospedeira microbiana, composição e uso de uma variante de subtilase.
US5837663A (en) 1996-12-23 1998-11-17 Lever Brothers Company, Division Of Conopco, Inc. Machine dishwashing tablets containing a peracid
AU8798198A (en) 1997-08-29 1999-03-22 Novo Nordisk A/S Protease variants and compositions
ES2536878T3 (es) 1997-10-13 2015-05-29 Novozymes A/S Mutantes de alfa-amilasa
WO2000034450A1 (en) 1998-12-04 2000-06-15 Novozymes A/S Cutinase variants
DE19819187A1 (de) 1998-04-30 1999-11-11 Henkel Kgaa Festes maschinelles Geschirrspülmittel mit Phosphat und kristallinen schichtförmigen Silikaten
US6242235B1 (en) * 1998-06-24 2001-06-05 Promega Corp. Polymerase stabilization by polyethoxylated amine surfactants
AU6078899A (en) 1998-10-13 2000-05-01 Novozymes A/S A modified polypeptide with reduced immune response
BR0009392B1 (pt) 1999-03-31 2012-06-12 mutante de um polipeptÍdeo com atividade de alfa-amilase, e, uso do polipeptÍdeo ou variante.
US6939702B1 (en) 1999-03-31 2005-09-06 Novozymes A/S Lipase variant
CA2394971C (en) 1999-12-15 2016-01-19 Novozymes A/S Subtilase variants having an improved wash performance on egg stains
EP1290150B1 (en) 2000-06-02 2005-08-24 Novozymes A/S Cutinase variants
AU2001278415A1 (en) 2000-08-01 2002-02-13 Novozymes A/S Alpha-amylase mutants with altered stability
DE10064983A1 (de) 2000-12-23 2002-07-18 Henkel Kgaa Neue Alkalische Protease aus Bacillus alcalophilus (DSM 11233)
DE10121463A1 (de) 2001-05-02 2003-02-27 Henkel Kgaa Neue Alkalische Protease-Varianten und Wasch- und Reinigungsmittel enthaltend diese neuen Alkalischen Protease-Varianten
DK200101090A (da) 2001-07-12 2001-08-16 Novozymes As Subtilase variants
DE10162728A1 (de) 2001-12-20 2003-07-10 Henkel Kgaa Neue Alkalische Protease aus Bacillus gibsonii (DSM 14393) und Wasch-und Reinigungsmittel enthaltend diese neue Alkalische Protease
DE10163883A1 (de) 2001-12-22 2003-07-10 Henkel Kgaa Neue Alkalische Protease aus Bacillus sp. (DSM 14390) und Wasch- und Reinigungsmittel enthaltend diese neue Alkalische Protease
DE10163884A1 (de) 2001-12-22 2003-07-10 Henkel Kgaa Neue Alkalische Protease aus Bacillus sp. (DSM 14392) und Wasch- und Reinigungsmittel enthaltend diese neue Alkalische Protease
CN1194099C (zh) 2002-04-27 2005-03-23 华南农业大学 快速检测有机磷农药残留的鱼酯酶试剂
WO2004003186A2 (en) 2002-06-26 2004-01-08 Novozymes A/S Subtilases and subtilase variants having altered immunogenicity
ATE420161T1 (de) * 2002-07-01 2009-01-15 Novozymes As Monopropylenglykol als fermentationszusatz
TWI319007B (en) 2002-11-06 2010-01-01 Novozymes As Subtilase variants
MXPA06005652A (es) 2003-12-03 2006-08-17 Genencor Int Perhidrolasa.
DE10360805A1 (de) 2003-12-23 2005-07-28 Henkel Kgaa Neue Alkalische Protease und Wasch- und Reinigungsmittel, enthaltend diese neue Alkalische Protease
DE602005009330D1 (de) * 2004-02-24 2008-10-09 Novozymes As Enzymstabilisierung in flüssigen waschmitteln
DE102004019751A1 (de) 2004-04-23 2005-11-17 Henkel Kgaa Neue Alkalische Proteasen und Wasch- und Reinigungsmittel, enthaltend diese neuen Alkalischen Proteasen
EP3620523A3 (en) 2004-07-05 2020-08-19 Novozymes A/S Alpha-amylase variants with altered properties
DE102005028295A1 (de) 2005-06-18 2006-11-16 Henkel Kgaa Proteasen aus psychrophilen Organismen
EP2385111B1 (en) 2005-07-08 2016-09-07 Novozymes A/S Subtilase variants
US8518675B2 (en) 2005-12-13 2013-08-27 E. I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
EP2371949B1 (en) 2006-01-23 2017-04-19 Novozymes A/S Lipase variants
ATE493893T1 (de) * 2006-03-10 2011-01-15 Basf Se Feste enymformulierungen und verfahren zu deren herstellung
US8071345B2 (en) * 2006-03-31 2011-12-06 Novozymes A/S Stabilized subtilisin composition
AU2008325250B2 (en) 2007-11-05 2013-06-13 Danisco Us Inc. Variants of Bacillus sp. TS-23 alpha-amylase with altered properties
US7919298B2 (en) 2008-02-29 2011-04-05 Novozymes A/S Polypeptides having lipase activity and polynucleotides encoding same
JP5973166B2 (ja) 2008-03-26 2016-08-23 ノボザイムス アクティーゼルスカブ 安定化された液体酵素組成物
US20110281324A1 (en) 2008-12-01 2011-11-17 Danisco Us Inc. Enzymes With Lipase Activity
CN102333914A (zh) 2009-03-06 2012-01-25 亨斯迈先进材料（瑞士）有限公司 酶催化的纺织物漂白-增白方法
CN102341495A (zh) 2009-03-10 2012-02-01 丹尼斯科美国公司 巨大芽孢杆菌菌株DSM90相关的α-淀粉酶及其使用方法
US20120028318A1 (en) 2009-03-18 2012-02-02 Danisco Us Inc. Fungal cutinase from magnaporthe grisea
EP2411510A2 (en) 2009-03-23 2012-02-01 Danisco US Inc. Cal a-related acyltransferases and methods of use, thereof
CA2775048A1 (en) 2009-09-25 2011-03-31 Novozymes A/S Use of subtilisin variants for cleaning proteinaceous stains on hard surfaces
US20120172280A1 (en) 2009-09-25 2012-07-05 Novozymes A/S Protease Variants
EP3190183B1 (en) 2009-12-09 2019-07-10 Danisco US Inc. Compositions and methods comprising protease variants
BR112012017056A2 (pt) 2009-12-21 2016-11-22 Danisco Us Inc "composições detergentes contendo lipase de bacillus subtilis e métodos para uso das mesmas"
WO2011084417A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing geobacillus stearothermophilus lipase and methods of use thereof
JP2013515139A (ja) 2009-12-21 2013-05-02 ダニスコ・ユーエス・インク サーモビフィダ・フスカのリパーゼを含む洗剤組成物、及びその使用方法
CN113186178A (zh) 2010-02-10 2021-07-30 诺维信公司 在螯合剂存在下具有高稳定性的变体和包含变体的组合物
WO2011150157A2 (en) 2010-05-28 2011-12-01 Danisco Us Inc. Detergent compositions containing streptomyces griseus lipase and methods of use thereof
US20140031272A1 (en) 2011-04-08 2014-01-30 Danisco Us Inc. Compositions
IN2014CN00597A (ko) 2011-06-30 2015-04-03 Novozymes As
JP6204352B2 (ja) 2011-06-30 2017-09-27 ノボザイムス アクティーゼルスカブ α−アミラーゼ変異体
WO2014007921A1 (en) 2012-06-08 2014-01-09 Danisco Us Inc. Variant alpha amylases with enhanced activity on starch polymers
WO2014055936A1 (en) * 2012-10-04 2014-04-10 Integenx Inc. Preservation of biological materials in non-aqueous fluid media
DK3174874T3 (da) * 2014-07-29 2020-12-07 Shenzhen Hightide Biopharmaceutical Ltd Berberinsalte, ursodeoxycholsalte og kombinationer, fremgangsmåder til fremstilling og anvendelse deraf.
US10995304B2 (en) 2014-12-15 2021-05-04 Novozymes A/S Subtilase variants
KR20190039192A (ko) * 2016-08-08 2019-04-10 바스프 에스이 액체 세탁 제형
CA3043443A1 (en) * 2016-12-01 2018-06-07 Basf Se Stabilization of enzymes in compositions
JP2021504546A (ja) * 2017-11-29 2021-02-15 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ 組成物、その製造方法および使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291334A1 (en) * 2017-11-29 2020-09-17 Basf Se Storage-stable enzyme preparations, their production and use
US11512268B2 (en) * 2017-11-29 2022-11-29 Basf Se Storage-stable enzyme preparations, their production and use

Also Published As

Publication number Publication date
KR20200088433A (ko) 2020-07-22
CA3083390A1 (en) 2019-06-06
RU2020121308A3 (ko) 2022-04-18
WO2019105781A1 (en) 2019-06-06
US20200291334A1 (en) 2020-09-17
CN111417707A (zh) 2020-07-14
EP3717611A1 (en) 2020-10-07
WO2019105780A1 (en) 2019-06-06
MX2020005661A (es) 2020-08-20
EP3717612A1 (en) 2020-10-07
CN111465680A (zh) 2020-07-28
RU2020121308A (ru) 2021-12-29
BR112020008695A2 (pt) 2020-10-27
JP2021504541A (ja) 2021-02-15
JP2021504546A (ja) 2021-02-15
BR112020010630A2 (pt) 2020-11-10
US11512268B2 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
EP3339436B1 (en) Detergent composition comprising protease variants
CN106715668A (zh) 清净剂组合物
US20190177665A1 (en) Liquid laundry formulation
JP2022504190A (ja) 液体中のヒドロラーゼを安定化する化合物
US20210071118A1 (en) Compositions, their manufacture and use
JP2022504229A (ja) 液体中のヒドロラーゼを安定化する化合物
RU2783163C2 (ru) Стабильные при хранении ферментные препараты, их получение и применение
US20220112479A1 (en) Compounds stabilizing amylases in liquids
WO2023088776A1 (en) Compositions comprising polymers, polymers, and their use
US20230235250A1 (en) Compositions and Their Use
WO2023088777A1 (en) Compositions comprising polymers, polymers, and their use
EP3677676A1 (en) Compounds stabilizing amylases in liquids
WO2023088761A1 (en) Compositions comprising polymers, polymers, and their use

Legal Events

Date Code Title Description
AS Assignment

Owner name: BASF SE, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUEFFER, STEPHAN;GARCIA MARCOS, ALEJANDRA;KELLERMEIER, MATTHIAS;AND OTHERS;SIGNING DATES FROM 20180102 TO 20180228;REEL/FRAME:052639/0416

Owner name: BASF SE, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUEFFER, STEPHAN;GARCIA MARCOS, ALEJANDRA;WOLWERTZ, SUSANNE;AND OTHERS;SIGNING DATES FROM 20180220 TO 20180316;REEL/FRAME:052639/0339

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION